We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

70 hedge funds and large institutions have $338M invested in Stemline Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

84% more capital invested

Capital invested by funds: $184M → $338M (+$154M)

25% more funds holding

Funds holding: 56 → 70 (+14)

5% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 21

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
70
Holders Change
+14
Holders Change %
+25%
% of All Funds
2.27%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
22
Reduced
21
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
SAC Capital Advisors
Connecticut
+$10.1M
2
Goldman Sachs
Goldman Sachs
New York
+$5.71M
3
Citadel Advisors
Citadel Advisors
Florida
+$5.11M
4
Franklin Resources
Franklin Resources
California
+$5.1M
5
DCM
Driehaus Capital Management
Illinois
+$4.24M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$16.4M
2
Neuberger Berman Group
Neuberger Berman Group
New York
-$5.43M
3
VAM
Visium Asset Management
New York
-$4.89M
4
BBA
Baker Bros. Advisors
New York
-$3.25M
5
FCM
Farallon Capital Management
California
-$2.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
51
American International Group
New York
$291K +$210K +6,432 New
TC
52
TFS Capital
Pennsylvania
$274K +$197K +6,047 New
ProShare Advisors
53
ProShare Advisors
Maryland
$262K +$188K +5,778 New
AllianceBernstein
54
AllianceBernstein
Tennessee
$218K -$36.9K -1,132 -19%
SO
55
STRS Ohio
Ohio
$177K -$13K -400 -9%
SG Americas Securities
56
SG Americas Securities
New York
$104K +$74.8K +2,292 New
SGAM
57
Smith Group Asset Management
Texas
$64K – – –
MP
58
Manifold Partners
California
$43K -$32.6K -1,000 -51%
Bank of America
59
Bank of America
North Carolina
$35K -$365K -11,184 -94%
SFPIA
60
Stevens First Principles Investment Advisors
California
$27K +$19.6K +600 New
BJ
61
BlackRock Japan
Japan
$26K -$29.8K -913 -62%
Ameriprise
62
Ameriprise
Minnesota
$26K – – –
Barclays
63
Barclays
United Kingdom
$15K -$4.53K -139 -29%
BlackRock
64
BlackRock
New York
$12K – – –
PNC Financial Services Group
65
PNC Financial Services Group
Pennsylvania
$9K – – –
Wells Fargo
66
Wells Fargo
California
$5K +$3.29K +101 New
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
$2K +$1.79K +55 New
Citigroup
68
Citigroup
New York
$1K -$6.85K -210 -95%
U
69
UBS
Switzerland
$1K +$815 +25 New
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$318 -$2.51K -77 -1%
Neuberger Berman Group
71
Neuberger Berman Group
New York
– -$5.43M -227,759 Closed
VM
72
VHCP Management
New York
– -$1.19M -50,000 Closed
ARTA
73
A.R.T. Advisors
New York
– -$481K -20,184 Closed
TRCT
74
Tower Research Capital (TRC)
New York
– -$12K -470 Closed
SSG
75
Summit Securities Group
New York
– -$1K -50 Closed
1 2
3

STML Hedge Fund Activity: Q3 2013 in Review

70 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2013, worth a combined $338M — up 84% from $184M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new STML positions and 5 closed out — a net gain of 15 holders — while 22 added to existing stakes and 21 trimmed.

The largest buyer was SAC Capital Advisors, adding an estimated $10.1M. The largest seller was Perceptive Advisors, cutting an estimated $16.4M.

  • 70 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2013, up from 56 in Q2 2013.
  • Funds reported $338M of Stemline Therapeutics, Inc. stock for Q3 2013, up 84% quarter-over-quarter.
  • 20 funds opened new Stemline Therapeutics, Inc. positions in Q3 2013 and 5 closed out, a net change of +15 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q3 2013 was SAC Capital Advisors, an estimated $10.1M added.
  • The largest Stemline Therapeutics, Inc. seller in Q3 2013 was Perceptive Advisors, an estimated $16.4M sold.

Based on aggregated 13F filings for Q3 2013.